These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36989958)

  • 1. Design, synthesis and pharmacological characterization of aminopyrimidine derivatives as BTK/FLT3 dual-target inhibitors against acute myeloid leukemia.
    Ran F; Liu Y; Zhu J; Deng X; Wu H; Tao W; Xie X; Hu Y; Zhang Y; Ling Y
    Bioorg Chem; 2023 May; 134():106479. PubMed ID: 36989958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of novel hydrazidoarylaminopyrimidine-based BTK/FLT3 dual inhibitors with potent in vivo anti-hematological malignancies effects.
    Ran F; Xie X; Wu Q; Wu H; Liu Y; Tao W; Sun Y; Wang R; Zhang Y; Ling Y
    Eur J Med Chem; 2023 Jan; 245(Pt 1):114913. PubMed ID: 36399923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.
    Lian X; Gao Y; Li X; Wang P; Tong L; Li J; Zhou Y; Liu T
    Bioorg Med Chem Lett; 2023 Nov; 96():129519. PubMed ID: 37838343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy.
    Zhang W; Yu G; Zhang H; Basyal M; Ly C; Yuan B; Ruvolo V; Piya S; Bhattacharya S; Zhang Q; Borthakur G; Battula V; Konopleva M; Rice WG; Andreeff M
    Haematologica; 2023 Jun; 108(6):1500-1514. PubMed ID: 36226489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-Aminopyrimidine derivatives as selective dual inhibitors of JAK2 and FLT3 for the treatment of acute myeloid leukemia.
    Xu S; Zhu Y; Meng J; Li C; Zhu Z; Wang C; Gu YC; Han L; Wen J; Tong M; Shi X; Hou Y; Liu Y; Zhao Y
    Bioorg Chem; 2023 May; 134():106442. PubMed ID: 36878064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of novel thieno[2,3-d]pyrimidine-based FLT3 inhibitors as anti-leukemic agents.
    Yang JS; Park CH; Lee C; Kim H; Oh C; Choi Y; Kang JS; Yun J; Jeong JH; Kim MH; Han G
    Eur J Med Chem; 2014 Oct; 85():399-407. PubMed ID: 25108079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.
    Dokla EME; Abdel-Aziz AK; Milik SN; McPhillie MJ; Minucci S; Abouzid KAM
    Bioorg Med Chem; 2022 Feb; 56():116596. PubMed ID: 35033885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor.
    Zhang L; Lakkaniga NR; Bharate JB; Mcconnell N; Wang X; Kharbanda A; Leung YK; Frett B; Shah NP; Li HY
    Eur J Med Chem; 2021 Dec; 225():113776. PubMed ID: 34479037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.
    Li X; Wang A; Yu K; Qi Z; Chen C; Wang W; Hu C; Wu H; Wu J; Zhao Z; Liu J; Zou F; Wang L; Wang B; Wang W; Zhang S; Liu J; Liu Q
    J Med Chem; 2015 Dec; 58(24):9625-38. PubMed ID: 26630553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of benzimidazole-indazole derivatives as potent FLT3-tyrosine kinase domain mutant kinase inhibitors for acute myeloid leukemia.
    Ko B; Jang Y; Kim MH; Lam TT; Seo HK; Jeong P; Choi M; Kang KW; Lee SD; Park JH; Kim M; Han SY; Kim YC
    Eur J Med Chem; 2023 Dec; 262():115860. PubMed ID: 37866334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases.
    Baska F; Sipos A; Őrfi Z; Nemes Z; Dobos J; Szántai-Kis C; Szabó E; Szénási G; Dézsi L; Hamar P; Cserepes MT; Tóvári J; Garamvölgyi R; Krekó M; Őrfi L
    Eur J Med Chem; 2019 Dec; 184():111710. PubMed ID: 31614258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural modifications at the 6-position of thieno[2,3-d]pyrimidines and their effects on potency at FLT3 for treatment of acute myeloid leukemia.
    Kim H; Lee C; Yang JS; Choi S; Park CH; Kang JS; Oh SJ; Yun J; Kim MH; Han G
    Eur J Med Chem; 2016 Sep; 120():74-85. PubMed ID: 27187860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and Synthesis of 4-(Heterocyclic Substituted Amino)-1
    Zhi Y; Wang Z; Yao C; Li B; Heng H; Cai J; Xiang L; Wang Y; Lu T; Lu S
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31731727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of orally active indirubin-3'-oxime derivatives as potent type 1 FLT3 inhibitors for acute myeloid leukemia.
    Jeong P; Moon Y; Lee JH; Lee SD; Park J; Lee J; Kim J; Lee HJ; Kim NY; Choi J; Heo JD; Shin JE; Park HW; Kim YG; Han SY; Kim YC
    Eur J Med Chem; 2020 Jun; 195():112205. PubMed ID: 32272419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel 4-azaaryl-N-phenylpyrimidin-2-amine derivatives as potent and selective FLT3 inhibitors for acute myeloid leukaemia with FLT3 mutations.
    Long Y; Yu M; Ochnik AM; Karanjia JD; Basnet SK; Kebede AA; Kou L; Wang S
    Eur J Med Chem; 2021 Mar; 213():113215. PubMed ID: 33516985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.
    Jagtap AD; Chang PT; Liu JR; Wang HC; Kondekar NB; Shen LJ; Tseng HW; Chen GS; Chern JW
    Eur J Med Chem; 2014 Oct; 85():268-88. PubMed ID: 25089810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3.
    Li Y; Ye T; Xu L; Dong Y; Luo Y; Wang C; Han Y; Chen K; Qin M; Liu Y; Zhao Y
    Eur J Med Chem; 2019 Nov; 181():111590. PubMed ID: 31408808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of 4-(4-aminophenyl)-6-methylisoxazolo[3,4-b] pyridin-3-amine covalent inhibitors as potential agents for the treatment of acute myeloid leukemia.
    Kang JB; Chen L; Leng XJ; Wang JJ; Cheng Y; Wu SH; Ma YY; Yang LJ; Cao YH; Yang X; Tong ZJ; Wu JZ; Wang YB; Zhou H; Liu JC; Ding N; Dai WC; Yu YC; Xue X; Sun SL; Dai XB; Chang L; Wang XL; Li NG; Shi ZH
    Bioorg Med Chem; 2022 Sep; 70():116937. PubMed ID: 35863236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and rational design of 2-aminopyrimidine-based derivatives targeting Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).
    Li Y; Wang P; Chen C; Ye T; Han Y; Hou Y; Liu Y; Gong P; Qin M; Zhao Y
    Bioorg Chem; 2020 Nov; 104():104361. PubMed ID: 33142418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and evaluation of pyrido.[3,4-b]pyrazin-2(1H)-one derivatives as potent FLT3 inhibitors.
    Sun M; Wang C; Wang P; Ye Q; Zhou Y; Li J; Liu T
    Bioorg Med Chem; 2023 Feb; 79():117155. PubMed ID: 36638621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.